Glenmark launches Ryaltris-AZ at affordable price in India

03 May 2021 Evaluate

Glenmark Pharmaceuticals has launched of Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.

Ryaltris-AZ nasal spray, developed by Glenmark, is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1079.45 8.15 (0.76%)
25-Apr-2024 09:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.00
Dr. Reddys Lab 5959.60
Cipla 1395.60
Zydus Lifesciences 933.95
Lupin 1583.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.